Charles M. Walworth, MD

Dr. Walworth did his undergraduate work at Georgetown University where he majored in biology with a minor in psychology. He completed medical school and residency training in internal medicine at Georgetown University School of Medicine. Dr Walworth re-directed his career (initially slated for urology) after working in a refugee camp on the Thai-Cambodian border, when the first five cases of AIDS were reported at Bangkok General Hospital. He completed a fellowship in infectious diseases at the National Institutes of Health and served as the HIV Clinical Trials Physician in the NIAID Clinical Trials Unit.

Dr. Walworth later entered private practice in Orange County, CA, where he built a very large HIV practice, conducted numerous clinical trials, served on speaker bureaus and advisory boards for several pharmaceutical companies, and worked closely with AIDS service organizations. In 2008 he joined Monogram Biosciences in South San Francisco, CA, initially as director of global medical affairs. He is now the associate vice president of medical affairs and education at Labcorp and also serves as co-discipline director for molecular infectious diseases.

Dr. Walworth is a member of the American College of Physicians, International AIDS Society. and the Infectious Diseases Society of America.

Scholarly Activities:

1. Chu C., Armenia D., Walworth C., Santoro C., and Shafer R. Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells. Clinical Microbiology Reviews. 2022; https://doi.org/10.1128/cmr.00052-22
2. Curanovic D, Martens S, Rodriguez M, Hammill H, Petropoulos C, Walworth C. HIV-1 DNA Testing in Viremic Patients Identifies More Drug Resistance than HIV-1 RNA Testing. Open Forum Infectious Disease. 2023; DOI: 10.1093/ofid/ofad146
3. Guideline Revision Contributor, Clinical and Laboratory Standards Institute. Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection. 2nd ed. CLSI Guideline M53. Clinical and Laboratory Standards Institute; 2023.
4. Parikh UM, Koss CA, Mellors JW, Walworth CM, et al. Early Virologic Success on Antiretroviral Therapy Following Breakthrough HIV Infection on Long-Acting Cabotegravir Pre-Exposure Prophylaxis. Open Forum Infectious Diseases; DOI:10.1093/ofid/ofaf285
5. Moyle G, Gruber J, Dunbar M, Radtchenko J, Frick A, Marongiu A, Sax P, Lim T, Santiago S, Benson P, Walworth C, Elion R. Outcomes in People with HIV Who Resume or Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Following an ART Treatment Interruption; AIDS DOI: 10.1097/QAD.0000000000004171
6. Khalifeh M, Rubin L, Dayya D, Walworth C, et al.  COVID-19 Neutralizing Antibody Titers in Maternal Blood, Umbilical Cord Blood, and Breast Milk. Journal of Perinatology 2023;44:28–34.

Areas of Support: Infectious Diseases: Molecular Infectious Diseases, HIV, Hepatitis, Vector Borne Diseases, STIs, SARS-CoV-2

Memberships: American College of Physicians, Infectious Diseases Society of America, International AIDS Society, California Physicians and Surgeon's Certificate

Board Certifications: Diplomate, National Board of Medical Examiners